Evidence map›Paper›PMID 22055504›Full record

Trial reportCell metabolism2011

Calorie restriction-like effects of 30 days of resveratrol supplementation on energy metabolism and metabolic profile in obese humans.

Silvie Timmers, Ellen Konings, Lena Bilet, Riekelt H Houtkooper, Tineke van de Weijer, Gijs H Goossens, Joris Hoeks, Sophie van der Krieken, Dongryeol Ryu, Sander Kersten and 7 more

4 registry-linked trialsOpen access · bronzeAbstract readMulticenter StudyRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Cell metabolism, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 4 registered trials, which are not on this map. Cited by 593 papers, 13 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
593citing papers in PubMed, 13 pooled it
51.0field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01504854 phase2completednot on this mapstarted 2012, after this paper: background citation

Phase II Study to Evaluate the Impact on Biomarkers of Resveratrol Treatment in Patients With Mild to Moderate Alzheimer's Disease

TypeinterventionalSponsorAlzheimer's Disease Cooperative Study (ADCS)Ran2012 to 2014Enrolled119ConditionsAlzheimer's DiseaseArmsResveratrol, Placebo
NCT01638780 naunknown statusnot on this mapstarted 2012, after this paper: background citation

Effect of Resveratrol on Insulin Sensitivity and Metabolic Profile in Type 2 Diabetics

TypeinterventionalSponsorMaastricht University Medical CenterRan2012 to 2014Enrolled24ConditionsType 2 DiabetesArmsplacebo, resveratrol
NCT02245932 nacompletednot on this mapstarted 2015, after this paper: background citation

The Effect of Resveratrol on Metabolism and Cardiovascular Risk Profile in Patients With Chronic Obstructive Pulmonary Disease (COPD)

TypeinterventionalSponsorMaastricht University Medical CenterRan2015 to 2017Enrolled23ConditionsPulmonary Disease, Chronic ObstructiveArmsResveratrol, Placebo
NCT04317287 naterminatednot on this mapstarted 2019, after this paper: background citation

A Double-blind, Randomized, Placebo-controlled, Parallel Design Study to Evaluate the Effects of the Cardio Formulation on Oxidized LDL in Individuals Who Are Overweight to Mildly Obese and Otherwise Healthy

TypeinterventionalSponsorSupplement Formulators, Inc.Ran2019 to 2021Enrolled9ConditionsOxidized Low Density LipoproteinArmsCardio formulation, Placebo
3 · Its place in the literature

Who cites it

593 citing papers in PubMed, 13 syntheses or guidelines pooled it, 1,276 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Pooled it
  10. Impact of Obesity-Induced Inflammation on Cardiovascular Diseases (CVD).International journal of molecular sciences · 2021
    Pooled it
  11. Pooled it
  12. Pooled it
  13. Pooled it
  14. Trial
  15. Trial
  16. Trial
  17. Trial
  18. Trial
  19. Trial
  20. Trial

533 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 5 institutions in 2 countries.

Silvie Timmers *Top Institute Food and Nutrition (TIFN), 6700 Wageningen, The Netherlands.
Ellen Konings *Department of Human Biology, NUTRIM School for Nutrition, Toxicology and Metabolism, Maastricht University Medical Center, 6200 Maastricht, The Netherlands.
Lena BiletDepartment of Human Biology, NUTRIM School for Nutrition, Toxicology and Metabolism, Maastricht University Medical Center, 6200 Maastricht, The Netherlands.
Riekelt H HoutkooperLaboratory for Integrative and Systems Physiology, Ecole Polytechnique Fédérale de Lausanne (EPFL), 1015 Lausanne, Switzerland.
Tineke van de WeijerDepartment of Human Biology, NUTRIM School for Nutrition, Toxicology and Metabolism, Maastricht University Medical Center, 6200 Maastricht, The Netherlands.
Gijs H GoossensDepartment of Human Biology, NUTRIM School for Nutrition, Toxicology and Metabolism, Maastricht University Medical Center, 6200 Maastricht, The Netherlands.
Joris HoeksDepartment of Human Biology, NUTRIM School for Nutrition, Toxicology and Metabolism, Maastricht University Medical Center, 6200 Maastricht, The Netherlands.
Sophie van der KriekenDepartment of Human Biology, NUTRIM School for Nutrition, Toxicology and Metabolism, Maastricht University Medical Center, 6200 Maastricht, The Netherlands.
Dongryeol RyuLaboratory for Integrative and Systems Physiology, Ecole Polytechnique Fédérale de Lausanne (EPFL), 1015 Lausanne, Switzerland.
Sander KerstenNutrition, Metabolism, and Genomics Group, Division of Human Nutrition, Wageningen University, 6700 Wageningen, The Netherlands.
Esther Moonen-KornipsDepartment of Human Biology, NUTRIM School for Nutrition, Toxicology and Metabolism, Maastricht University Medical Center, 6200 Maastricht, The Netherlands.
Matthijs K C HesselinkHuman Movement Sciences, NUTRIM School for Nutrition, Toxicology and Metabolism, Maastricht University Medical Center, 6200 Maastricht, The Netherlands.
Iris KunzDSM Nutritional Products Ltd., 4303 Kaiseraugst, Switzerland.
Vera B Schrauwen-HinderlingRadiology, NUTRIM School for Nutrition, Toxicology and Metabolism, Maastricht University Medical Center, 6200 Maastricht, The Netherlands.
Ellen BlaakDepartment of Human Biology, NUTRIM School for Nutrition, Toxicology and Metabolism, Maastricht University Medical Center, 6200 Maastricht, The Netherlands.
Johan AuwerxLaboratory for Integrative and Systems Physiology, Ecole Polytechnique Fédérale de Lausanne (EPFL), 1015 Lausanne, Switzerland.
Patrick SchrauwenTop Institute Food and Nutrition (TIFN), 6700 Wageningen, The Netherlands.
Maastricht University · NLÉcole Polytechnique Fédérale de Lausanne · CHTiFN · NLDSM (Switzerland) · CHWageningen University & Research · NL

Funding

European Research Council 231138
6 · The paper itself

Abstract

Resveratrol is a natural compound that affects energy metabolism and mitochondrial function and serves as a calorie restriction mimetic, at least in animal models of obesity. Here, we treated 11 healthy, obese men with placebo and 150 mg/day resveratrol (resVida) in a randomized double-blind crossover study for 30 days. Resveratrol significantly reduced sleeping and resting metabolic rate. In muscle, resveratrol activated AMPK, increased SIRT1 and PGC-1α protein levels, increased citrate synthase activity without change in mitochondrial content, and improved muscle mitochondrial respiration on a fatty acid-derived substrate. Furthermore, resveratrol elevated intramyocellular lipid levels and decreased intrahepatic lipid content, circulating glucose, triglycerides, alanine-aminotransferase, and inflammation markers. Systolic blood pressure dropped and HOMA index improved after resveratrol. In the postprandial state, adipose tissue lipolysis and plasma fatty acid and glycerol decreased. In conclusion, we demonstrate that 30 days of resveratrol supplementation induces metabolic changes in obese humans, mimicking the effects of calorie restriction.

Indexed as

Adipose TissueAlanine TransaminaseAMP-Activated Protein Kinase KinasesBlood GlucoseBlood PressureCaloric RestrictionCitrate (si)-SynthaseCross-Over StudiesDouble-Blind MethodEnergy MetabolismFatty AcidsGlycerolHeat-Shock ProteinsHumansLiverMaleAlanine TransaminaseAMP-Activated Protein Kinase KinasesBlood GlucoseCitrate (si)-SynthaseFatty AcidsGlycerolHeat-Shock ProteinsPeroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alphaPPARGC1A protein, humanProtein KinasesResveratrolSIRT1 protein, humanSirtuin 1StilbenesTranscription FactorsTriglycerides

Identifiers

PMID22055504
PMCPMC3880862
OpenAlexW2165722123

What Socratic holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.